sur Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma's Annual General Meeting 2026 Overview
Heidelberg Pharma AG held its Ordinary Annual General Meeting on June 23, 2026. Shareholders approved all management proposals with substantial majorities, ranging from 98.67% to 98.72%. Key resolutions included formally approving the Management and Supervisory Boards for the 2024/2025 financial year and appointing auditors for 2025/2026.
Notably, Jack Yefei Ling was elected as a new member of the Supervisory Board. Additionally, a resolution was passed to reduce the size of the Supervisory Board from seven to five members. Attendance at the meeting, including postal votes, represented 80.55% of the capital stock.
Heidelberg Pharma, based in Ladenburg, Germany, focuses on developing Antibody Drug Conjugates (ADCs) and is publicly traded on the Frankfurt Stock Exchange.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Heidelberg Pharma AG